Researchers at Université de Montréal have identified a unique genetic signature in immune cells that could revolutionize the diagnosis of Parkinson’s disease. Published in the journal Brain, the study used advanced single-cell RNA sequencing to pinpoint activated immune cells and stress-response genes in Parkinson’s patients, offering a potential blood-based diagnostic tool. This breakthrough may enable earlier and more accurate detection, distinguishing Parkinson’s from similar disorders like Parkinsonian syndromes.
Led by neuroscientist Martine Tétreault, the team analyzed blood samples from 14 Parkinson’s patients, 6 individuals with Parkinsonian syndromes, and 10 healthy controls. They discovered that immune cells in Parkinson’s patients exhibited heightened activity and overexpressed genes linked to stress responses, forming a distinct disease signature.
“Single-cell RNA-seq allowed us to see gene expression at the cellular level, revealing biomarkers that could transform diagnosis,” explained Tétreault. The findings could also aid in differentiating Parkinson’s from rare conditions such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).
The researchers are now sharing a comprehensive immune cell atlas with the scientific community to further accelerate research. With 110,000 Canadians currently living with Parkinson’s—a number projected to rise to 150,000 by 2034—this tool could significantly improve patient outcomes and clinical trial efficiency.
This study marks a critical step toward non-invasive, early Parkinson’s detection. By leveraging immune cell biomarkers, the research opens doors to more reliable diagnostics and targeted therapies, addressing a pressing need in neurodegenerative disease management. Future work will focus on validating these findings in larger patient cohorts.
Add comment